Amyotrophic lateral sclerosis: From research to therapeutic attempts and therapeutic perspectives

Current Medicinal Chemistry

Volumn 18, Issue 36, 2011, Pages 5655-5665

  Contestabile, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Amyotrophic lateral sclerosis; Animal models; Clinical trials; Excitotoxicity; Gene therapy; Mitochondrial damage; Neuroinflammation; Neurotrophic factors; Oxidative stress; Protein aggregates; Stem cells; Therapy

Indexed keywords

4 PHENYLBUTYRIC ACID; AEOL 10150; ALPHA TOCOPHEROL; ANTIOXIDANT; CELASTROL; CELECOXIB; DEXTROMETHORPHAN; GABAPENTIN; GLATIRAMER; GLUTATHIONE; LAMOTRIGINE; LITHIUM; MINOCYCLINE; NITRIC OXIDE SYNTHASE; RILUZOLE; SELEGILINE; UBIDECARENONE; UNCLASSIFIED DRUG; VALPROIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; DRUG TARGETING; ENCEPHALITIS; EXCITOTOXICITY; GENE THERAPY; HUMAN; MICROGLIA; NONHUMAN; OXIDATIVE STRESS; PROTEIN FOLDING; REVIEW; STEM CELL TRANSPLANTATION;

EID: 84055192382     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798347289     Document Type: Review

References (227)

1. Kurtzke, J.F. Epidemiology of amyotrophic lateral sclerosis. Adv. Neurol., 1982, 36, 281-302.
2. Cox, P.A.; Banack, S; Murch, S.J. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc. Natl. Acad. Sci. USA, 2003, 100, 13380-3. (Pubitemid 37444750)
3. Kasarskis, E.J.; Lindquist, J.H.; Coffman, C.J.; Grambow, S.C.; Feussner J.R.; Allen, K.D.; Oddone, E.Z.; Kamins, K.A.; Horner, R.D. Clinical aspects of amyotrophic lateral sclerosis among Gulf war veterans. Amyotroph. Lat. Scler., 2009, 10, 35-41.
4. Chio, A.; Benzi, G.; Dossena, M.; Mutani, R.; Mora, G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain, 2005, 128, 472-6. (Pubitemid 40380183)
5. Leigh, P.N. Amyotrophic lateral sclerosis. In: Eisen, A.A. and Shaw, P.J. (Eds.) , Motor Neuron Disorders and Related Diseases. Elsevier, Edinburgh, 2007, pp. 249-78.
6. Selverstone, V.J.; Doucette, P.A.; Zittin, P.S. Copper-Zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem., 2005, 74, 563-93. (Pubitemid 40995518)
7. Al-Chalabi, A.; Leigh, P.N. Familial amyotrophic lateral sclerosis and related motor neuron disorders. In: Emery, A.E.H. (Ed.), Neuromuscular Disorders: Clinical and Molecular Genetics, John Wiley & Sons, Chichester, 2006, pp. 433-67.
8. Gurney, M.E.; Pu, H.; Chiu, A.Y.; Dal Canto, M.C.; Polchow, C.Y.; Alexander, D.D.; Caliendo J.; Hentati, A. et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science, 1994, 264, 1772-5. (Pubitemid 24227760)
9. Bendotti, C.; Carri, M.T. Lessons from models of SOD1-linked familial ALS. Trends Mol. Med., 2004, 10, 393-400. (Pubitemid 39061141)
10. Valentine, J.S.; Doucette, P.A.; Zittin Potter, S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis.Annu. Rev. Biochem., 2005, 74, 563-98.
11. Figlewicz, D.A.; Krizus, A., Martinoli, M.; Meininger, V.; Dib, M.; Rouleau, G.A.; Julien, J.P. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Gen., 1994, 3, 1757-61. (Pubitemid 24310467)
12. Yang, Y.; Hentati, A.; Deng, H.X.; Dabbagh, O.; Sasaki, T.; Hirano, M.; Hung, W.Y.Ouahchi, K. et al. The gene encoding Alsin, a protein with three guanine nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet., 2001, 29, 160-5. (Pubitemid 32952652)
13. Floyd, R.A. Antioxidants, oxidative stress and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med., 1999, 333, 236-45. (Pubitemid 129708638)
14. Contestabile, A. Oxidative stress in neurodegeneration: mechanisms and therapeutic perspectives. Curr. Topics Med. Chem., 2001, 1, 553-68.
15. Halliwell, B.; Gutteridge, J.M.C. Free Radicals in Biology and Medicine. 3rd. ed., Oxford University press, Oxford, 1999.
16. Polazzi, E.; Contestabile, A. Reciprocal interactions between microglia and neurons: from serviva to neuropathology. Rev. Neurosci., 2002, 13, 221-42. (Pubitemid 35178154)
17. Contestabile, A.; Monti, B.; Contestabile, A.; Ciani, E. Brain nitric oxide and its dual role in neurodegeneration/neuroprotection: understanding molecular mechanisms to devise drug approaches. Curr. Med. Chem., 2003, 10, 2147-74. (Pubitemid 37139068)
18. Beckman, J.S.; Koppenol, W.H. Nitric oxide, superoxide and peroxinitrite: the good, the bad and the ugly. Am. J. Physiol., 1996, 271, C1424-37.
19. Shaw, P.J.; Egget, C.J. Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J: Neurol., 2000, 247, 17-27. (Pubitemid 30182083)
20. Barber, S.C.; Mead, R.J.; Shaw, P.J. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim. Biophys. Acta, 2006, 1762, 1051-67. (Pubitemid 44750575)
21. Genova, M.I.; Pich, M.M.; Bernacchia, A.; Bianchi, C.; Biondi, A.; Bovina, C.; Falasca, A.I.; Formiggini G., Parenti-Castelli, G.; Lenaz, G. The mitochondrial production off reactive oxygen species in relation to aging and pathology. Ann. N. Y. Acad. Sci., 2004, 1011, 86-100. (Pubitemid 38608395)
22. Louvel, E.; Hugon, J.; Doble, A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol. Sci., 1997, 18, 196-203. (Pubitemid 27283649)
23. Ince, P.C.; Stout, N.; Shaw, P.; Slade, J.; Hunziker, W.; Heizmann, C.W.; Baimbridge, K.G. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron diseases.Neuropathol. Appl. Neurobiol., 1993, 19, 291-9. (Pubitemid 23237479)
24. Andreassen, O. A.; Dedeoglu, A.; Klivenyi, P.; Beal, M. F.; Bush, A. I. Nacetyl-Lcysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport. 2000, 11, 2491-3. (Pubitemid 30622295)
25. Louwerse, E. S.; Weverling, G. J.; Bossuyt, P. M.; Meyjes, F. E.; de Jong, J. M. Randomized, CNTFdouble-blind, controlled trial of acetylcysteine in amyotrophiclateral sclerosis. Arch. Neurol., 1995, 52, 559-64.
26. Andrews, Z.B.; Diano, S.; Horvath, T.L. Mitochondrial uncoupling proteins inthe CNS: in support of function and survival. Nat. Rev. Neurosci., 2005, 6, 829-40. (Pubitemid 41568725)
27. Noack, H.; Kube, U.; Augustin, W. Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Rad. Res., 1994, 20, 375-86. (Pubitemid 24170147)
28. Beal, M.F. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Rad. Res., 2002, 36, 455-60. (Pubitemid 35154095)
29. Matthews, R.T.; Yang, L.; Browne, S.; Baik, M.; Beal, M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects, Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 8892-7.
30. Ferrante, K.L.; Shefner, J.; Zhang, H.; Betensky, R.; O'Brien, M.; Yu, H.; Taft, J.; Beal M.F. et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology, 2005, 65, 1834-6.
31. Levy, G.; Kaufmann, P.; Buchsbaum, R.; Montes, J.; Bardsdorf, A.; Arbing,R.; Battista, V.; Zhou, X. et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology, 2006, 66, 660-3. (Pubitemid 43739818)
32. Kaufmann, P.; Thompson, J.L.; Levy, G.; Buchsbaum, R.; Shefner, J.; Krivickas, L.S.; Katz, J. Rollins, Y. et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol., 2009, 66, 235-44.
33. Tucker, J.M.; Townsend, D.M. Alpha-tocopherol: roles in prevention and therapy of human disease, Biomed. Pharmacother., 2005, 59, 380-7. (Pubitemid 41219652)
34. Desnuelle, C.; Dib, M.; Garrel, C.; Favier, A. A double-blind, placebocontrolled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol study group. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2001, 2, 9-18. (Pubitemid 32472143)
35. Graf, M.; Ecker, D.; Horowski, R.; Kramer, B.; Riederer, P.; Gerlach, M.; Hager, C.; Ludolph, A.C. et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study, J. Neur. Transm., 2005, 112, 649-60. (Pubitemid 40591197)
36. Patel, M.; Day, B.J. Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol. Sci., 1999, 20, :359-64. (Pubitemid 29421616)
37. Crow, J.P.; Calingasan, N.Y.; Chen, J.; Hill, J.L.; Beal, M.F. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol., 2005, 258-65. (Pubitemid 41098883)
38. Lange, D.J.; Murphy, P.L.; Diamond, B.; Appel, V.; Lai, E.C.; Younger, D.S.; Appel, S.H. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch. Neurol., 1998, 55, 93-6. (Pubitemid 28139110)
39. Mazzini, L.; Testa, D.; Balzarini, C.; Mora, G. An open randomized clinical trial off selegeline in amyotrophic lateral sclerosis. J. Neurol., 1994, 241, 223-7. (Pubitemid 24072934)
40. Tan, D.X.; Reiter, R.J.; Manchester, L.C.; Yan, M.T.; El-Sawi, M.; Sainz, R.M.; Mayo, J.C.; Kohen, R. et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem., 2002, 2, 181-97.
41. Reiter, R.J. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol., 1998, 56, 359-84. (Pubitemid 28389724)
42. Weishaupt, J.H.; Bartels, C.; Polking, E.; Dietrich, J.; Rohde, G.; Poeggeler, B.; Mertens, N.; Sperling, S. et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res., 2006, 41, 313
43. Dugan, L.L.; Lovett, E.G.; Quick, K.L.; Lotharius, J.; Lin, T.T.; O'Malley, K.L. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat. Disord., 2001, 7, 243-6. (Pubitemid 32372506)
44. Ali, S.S.; Hardt,J.I.; Quick, K.L.; Kim-Han, J.S.; Erlanger,B.F.; Huang, T.T.,Epstein, C.J.; Dugan, L.L. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties, Free Rad. Biol. Med., 2004, 37, 1191-202. (Pubitemid 39296744)
45. Dugan, L.L.; Turetsky, D.M.; Du, C.; Lobner, D.; Wheeler, M.; Almli, C.R.; Shen, C.K.; Luh,T.Y.; Choi, T.W.; Lin, T.S. Carboxyfullerenes as neuroprotective agents, Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 9434-9. (Pubitemid 27357847)
46. Bremer, J. Carnitine-metabolism and functions. Physiol Rev., 1983, 63,1420-80.
47. Hagen, T.M.; Liu, J.; Lykkesfeldt, J.; Wehr, C.M.; Ingersoll, R.T.; Vinarsky, V.; Bartholomew J.C.; Ames, B.N. Feeling acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc. Natl. Acad. Sci. U.S.A., 2002,1870-5. (Pubitemid 34168981)
48. Kira, Y.; Nishikawa, M.; Ochi,, A.; Sato, E.; Inoue, M. L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Res., 2006, 1070, 206-14. (Pubitemid 43247760)
49. Choi, D. Glutamate neurotoxicity and diseases of the nervous system, Neuron, 1988, 1, 623-34.
50. Sattler, R.; Tymianski, M. Molecular mechanisms of glutamate receptor mediated excitotoxic neuronal cell death, Mol. Neurobiol., 2001, 24, 107-29. (Pubitemid 34066681)
51. Duncan, M. W.; Steele, J. C.; Kopin, I. J.; Markey, S. P. 2-Amino-(methylamino)-propanoic acid in cycad flour: an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia. Neurology, 1990, 40, 767-72. (Pubitemid 20159611)
52. Spencer, P. S.; Roy, D.N.; Ludolph, A.; Hugon, J.; Dwivedi, M.P.; Schaumburg, H.H. Lathyrism: evidence for the role of the excitatory aminoacid BOAA. Lancet, 1986, 8506, 1066-7. (Pubitemid 17173955)
53. Plaitakis, A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis. Ann. Neurol., 1990, 28, 3-8 (Pubitemid 20222144)
54. Shaw, P.J.; Forrest, V.; Ince, P.G.; Richardson, J.P.; Wastell, H.J. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration, 1995,4, 209-16..
55. Spreux-Varoquaux, O.; Bensimon, G.; Lacomblez, L.; Salachas, F.; Pradat, P.F.; Le Forestier, N.; Marouan, A.; Dib, M.; Meininger, V. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J. Neurol. Sci. 2002, 193, 73-8. (Pubitemid 34098937)
56. Rothstein, J.D.; Van Kammen, M.; Levey, A.I.; Martin, L.J.; Kuncl, R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol., 1995, 38, 73-84.
57. Shaw, P.J.; Chinnery, R.M.; Ince, P.G. Non-NMDA receptors in motor neuron disease (MND): a quantitative autoradiographic study in spinal cord and motor cortex using [3H]CNQX and [3H] kainate. Brain Res., 1994, 655, 186-94. (Pubitemid 24263008)
58. Shaw, P.J.; Ince, P.G. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J. Neurol., 1997, 244 (Suppl.), S3-S14. (Pubitemid 27208005)
59. Shaw, P.J.; Ince, P.G.; Johnson, M.; Perry, E.K.; Candy, J.M. The quantitative autoradiographic distribution of [3H]MK-801 binding sites in the normal human brainstem in relation to motor neuron disease. Brain Res., 1991, 572, 276-80
60. Shaw, P.J.; Ince, P.G.; Matthews, J.N.S.; Johnson, M.; Candy, J.M. Nmethyl-D-aspartate (NMDA) receptors in the spinal cord and motor cortex in motor neurone disease: a quantitative autoradiographic study using [3H]MK-801. Brain Res., 1994, 637, 297-302. (Pubitemid 24061063)
61. Tortarolo, M.; Grignaschi,G., Calvaresi, N.; Zennaro, E.; Spaltro, G.; Colovic, M.; Fracasso, C.; Guiso, G. et al. Glutamate AMPA receptors change in motor neurons of SOD1(G93A) transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease. J. Neurosci. Res., 2006, 8, 134-46. (Pubitemid 43062017)
62. Volterra, A.; Trott, D.; Cassutti, P.; Tromba, C.; Salvaggio, A.; Melcangi, R.C.; Racagni, G. High sensitivity of glutamate uptake to extracellular free arachidonic acid levels in rat cortical synaptosomes and astrocytes. J. Neurochem. 1992, 59, 600-6.
63. Canton, T.; Pratt, J.; Stutzmann, J.M.; Imperato, A.; Boireau, A. Glutamate uptake is decreased tardively in the spinal cord of FALS mice. NeuroReport, 1998, 9, 775-8. (Pubitemid 28179273)
64. Fray, A.E.; Banner. S.J.; Ince, P.G.; Milton, I.D.; Usher, P.A.; Shaw, P.J. Expression of the glial glutamate transporter EAAT2 in motor neurone disease: an immunocytochemical study. Eur. J. Neurosci., 1998, 10, 2481-9 (Pubitemid 28362556)
65. Cheah, B.C.; Vucic, S.; Krishnan, A.V.; Kiernan, M.C. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem., 2010, 17, 1942-9.
66. Gurney, M.E.; Cutting, F.B.; Zhai, P.; Doble, A.; Taylor, C.P.; Andrus, P.K.; Hall, E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol., 1996, 39, 147-57. (Pubitemid 26071564)
67. Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. The ALS/Riluzole Study Group.New. Engl. J. Med., 1994, 330, 585-91. (Pubitemid 24065791)
68. Lecomblez, L.; Bensimon, G.; Leigh, P.N.; Guillet, P.; Meininger, V. and the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet, 1996, 347, 1425-31. (Pubitemid 26161204)
69. Bensimon, G.; Lacomblez, L.; Delumeau, J.C.; Bejuit, R.; Truffinet, P.; Meininger, V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J. Neurol., 2002, 249, 609-15. (Pubitemid 34516368)
70. Miller, R.G.; Mitchell, J.D.; Lyon, M.; Moore, D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev, 2007, CD001447, doi:10.1002/14651858.CD001447. pub2.
71. Eisen, A.; Stewart, H.; Schulzer, M.; Cameron, D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can. J. Neurol. Sci., 1993, 20, 297-301. (Pubitemid 24013591)
72. Van Damme, P.; Leyssen, M.; Gallewaert, G.; Robberecht, W.; Van Den Bosch, L. The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett., 2003, 343, 81-4. (Pubitemid 36577521)
73. Sonkusare, S.K.; Kaul, C.L.; Ramarao, P. Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol. Rev., 2005, 51, 1-17. (Pubitemid 39425068)
74. Wang, R.; Zhang, D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur. J. Neurosci., 2006, 22, 2376-80.
75. Joo. I.S.; Hwang, D.H.; Seok, J.I.; Shin, S.K.; Kim, S.U. Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Clin. Neurol., 2007, 3, 181-6.
76. de Carvalho, M.; Pinto, S.; Cota, J.; Evangelista, T.; Ohana, B.; Pinto, A. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph. Lat. Scler., 2010, 11, 456.60.
77. Askmark, H.; Aquilonius, S.M.; Gillberg, P.G.; Liedholm, L.J.; Stalberg, E.; Wuopio, R.A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry, 1993, 56, 197-200 (Pubitemid 23075416)
78. Appelbaum, J. S.; Roos, R.P.; Salazar-Grueso, E.F.; Buchman, A.; Iannacone, S.; Giantz, R.; Siddique, T.; Maselli, R. Intrafamilial heterogeinity in hereditary motor neuron disease. Neurology 1992, 42, 1488-92.
79. Blin, O.; Azulay, J.P.; Desnuelle, C.; Billé-Turc F.; Braguer, D.; Besse, D.; Branger, E.; Crevat, A. et al. A controlled one year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin. Neuropharmacol., 1996, 19, 189-92. (Pubitemid 26099377)
80. Kawamata. T.; Akiyama, H.; Yamada, T.; McGeer, P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol.. 1992, 140, 691-707.
81. Troost. D.; Van den Oord. J.J.; Vianney de Jong, J.M.B. Immunohistochemical characteristics of the inflammatory infiltration in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol., 1990, 16, 401-10. (Pubitemid 20334861)
82. Penfield, W. Microglia and the process of phagocytosis in gliomas. Am. J. Pathol., 1925, 1, 77-89.
83. Luber-Narod, J.; Rogers, J. Immune system associated antigens expressed by cells of the human central nervous system. Neurosci. Lett., 1988, 94, 265-73.
84. McGeer, P.L.; Itagaki, S.; McGeer, E.G. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol., 1988, 76, 550-7.
85. Kawamata, T.; Akiyama, H.; Yamada, T.; McGeer, P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992, 140, 691-707.
86. Holmoy, T. T cells in amyotrophic lateral sclerosis. Eur. J. Neurol., 2008, 15, 360-6. (Pubitemid 351424091)
87. Kerschensteiner, M. Strategies for axonal repair in central nervous system diseases. J. Neurol., 2007, 254, 29-32.
88. Hohlfeld, R. Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis? J. Neurol. Sci., 2008, 265, 93-6.
89. Polazzi, E.; Monti, B. Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog. Neurobiol., 2010, 92, 293-315.
90. Venters, H.D.; Dantzer, R.; Kelley, K.W. A new concept in neurodegeneration: TNFalpha is a silencer of survival signals. Trends Neurosci . 2000, 23, 175-80. (Pubitemid 30151214)
91. Poloni, M.; Facchetti, D.; Mai, R.; Micheli, A.; Agnoletti, L.; Francolini, G.; Mora, G.; Camana, C. et al. Circulating levels of tumour necrosis factoralpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 2000, 287, 211-4. (Pubitemid 30339386)
92. Yoshihara, T.; Ishigaki, S.; Yamamoto, M.; Liang, Y.; Niwa, J.; Takeuchi, H.; Doyu, M.; Sobue, G. Differential expression of inflammation-and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem., 2002, 80, 158-67. (Pubitemid 34614588)
93. Hensley, K.; Fedynyshyn, J.; Ferrell, S.; Floyd, R.A.; Gordon, B.; Grammas, P.; Hamdheydari, L.; Mhatre, M. et al. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol. Dis., 2003, 14, 74-80. (Pubitemid 37103181)
94. Yasojima, K.; Tourtellotte, W.W.; McGeer, E.G.; McGeer, P.L. Marked increase in cyclooxygenase-2 in ALS spinal cord. Neurology, 2001, 57, 952-6. (Pubitemid 32880185)
95. McGeer, P.L.; McGeer, E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve, 2002, 26, 459-70.
96. Ackerley, S.; Grierson, A.J.; Banner, S.; Perkinton, M.S.; Brownlees, J.; Byers, H.L.; Ward, M.; Thornhill, P. et al. p38a stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol. Cell. Neurosci., 2004, 26, 354-64. (Pubitemid 38781091)
97. Veglianese, P.; Lo Coco, D.; Bao Cutrona, M.; Magnoni, R.; Pennacchini, D.; Pozzi, B.; Gowing, G.; Julien J.P. et al. Activation of the p38MAPK cascade is associated with upregulation of TNF a receptors in the spinal motor neurons of mouse models of familial ALS. Mol. Cell. Neurosci.. 2006, 31, 218-31. (Pubitemid 43214532)
98. Yrjanheikki, J.; Tikka, T.; Keinanen, R.; Goldsteins, G.; Chan, P.H.; Koistinaho, J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA, 1999, 96, 13496-500.
99. Chen, M.; Ona, V.O.; Li, M.; Ferrante, R.J.; Fink, K.B.; Zhu, S.; Bian, J.; Guo, L.; Farrel, L.A.; Hersch, S.M.; Hobbs, W.; Vonsattel, J.P.; Cha, J.H.; Friedlander, R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model off Huntington disease. Nat. Med., 2000, 6, 797-801. (Pubitemid 30469429)
100. Sanchez Mejia, R.O.; Ona, V.O.; Li, M.; Friedlander, R.M. Minocycline reduces traumatic brain injury-mediated caspase-1 activation tissue damage and neurological dysfunction. Neurosurgery, 2001, 48, 1393-99.
101. Kriz, J.; Nguyen, M.D.; Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis., 2002, 10, 268-78. (Pubitemid 35217580)
102. Zhu, S.; Stavrovskaya, I.G.; Drozda, M.; Kim, B.Y.; Ona, V.; Li, M.; Sarang, S.; Liu, A.S. et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature, 2002, 417, 74-78. (Pubitemid 34498818)
103. Van Den, B.L.; Tilkin, P.; Lemmens, G.; Robberecht, W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport, 2002, 13, 1067-70. (Pubitemid 34587742)
104. Zhang, W.; Narayanan, M.; Friedlander, R.M. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol., 2003, 53, 267-70. (Pubitemid 36164012)
105. Keller, A.F.; Gravel, M.; Kriz, J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp. Neurol., 2010, Epub ahead of print.
106. Gordon, P.H.; Moore, D.H.; Gelinas, D.F.; Qualls, C.; Meister, M.E.; Werner, G.; Mendoza, M.; Mass, J.; Kushner, G.; Miller, M.G. Placebocontrolled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology, 2004, 62, 1845-7. (Pubitemid 38661748)
107. Pontieri, F.E.; Ricci, A.; Pellicano, C.; Benincasa, D.; Buttarelli, F.R. Minocycline in amyotrophic lateral sclerosis. Neurol. Sci., 2005, 26, 285-7.
108. Gordon, P.H.; Moore, D.H.; Miller, R.G.; Florence, J.M.; Verheijde, J.L.; Doorish, C.; Hilton, J.F.; Spitalny, G.M.; MacArthur, R.B.; Mitsumoto, H.; Neville, H.E.; Boylan, K.; Mozaffar, T.; Belsh, J.M.; Ravits, J.; Bedlack, R.S.; Graves, M.C.; McCluskey, L.F.; Barohn, R.J.; Western ALS Study Group. Efficacy off minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol., 2007, 6, 1045-53. (Pubitemid 350116691)
109. Allison, A.C.; Cacabelos, R.; Lombardi, V.R.; Alvarez, X.A.; Vigo, C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiat., 2001, 25, 1341-57. (Pubitemid 33022713)
110. Westerheide, S.D.; Bosman, J.D.; Mbadugha, B.N.; Kawahara, T.L.; Matsumoto, G.; Kim, S.; Gu, W.; Devlin, J.P. et al. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem., 2004, 279, 56053-60. (Pubitemid 40066613)
111. Kiaei, M.; Kipiani, K.; Petri, S.; Chen, J.; Calingasan, N.Y.; Beal, M.F. Celastrol blocks neuronal cell death and extends life in transgenic mouse model off amyotrophic lateral sclerosis. Neurodegener. Dis., 2005, 2, 246-54. (Pubitemid 43805908)
112. Pompl, P.N.; Ho, L.; Bianchi, M.; McManus, T.; Qin, W.; Pasinetti, G.M. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J., 2003, 17, 725-27.
113. Klivenyi, P.; Klael, M.; Gardian, G.; Callingsan, N.Y.; Beal, M.F. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem., 2004, 88, 576-82. (Pubitemid 38140202)
114. Cudkowicz, M.E.; Shefner, J.M.; Schoenfeld. D.; Zhang, H.; Andreasson, K.I.; Rothstein, J.D.; Drachman, D.B. Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol., 2006, 60, 22-31.
115. FitzGerald, G.A. Coxibs and cardiovascular disease. N. Engl. J. Med., 2004, 351, 1709-11.
116. Haverkamp, L.J.; Smith, R.G.; Appel, S.H. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann. Neurol.,1994, 36, 253-4. (Pubitemid 24239249)
117. Angelov, D.N.; Waibel, S.; Guntinas-Lichius, O.; Lenzen, M.; Neiss, W.F.; Tomov, T.L.; Yoles, E.; Kipnis, J.; Scori, H.; Reuter, A.; Ludolph, A.; Schwartz, M. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. Usa, 2003, 101, 4790-95. (Pubitemid 36457807)
118. Habish, H.J.; Schwalenstocker, B.; Danzeisen, R.; Neuhaus, O.; Hartung, H.P.; Ludolph, A. Limited effects of glatiramer acetate in the high copy number hSOD1-G93A mouse model of ALS. Exp. Neurol. ,2007, 206, 288-95. (Pubitemid 47094773)
119. Haenggel, C.; Julien, J.P.; Mosley, R.L.; Perez, N.; Dhar, A.; Gendelman, H.E.; Rothstein, J.D. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiol Dis., 2007, 26, 146-52. (Pubitemid 46436494)
120. Gordon, P.H.; Doorish, C.; Montes, J.; Mosley, R.L.; Diamond, B.; Macarthur, R.B.; Weimer, L.H.; Kaufmann, P.; Hays, A.P.; Rowland, L.P.; Gendelman, H.E.; Przedborski, S.; Mitsumoto, H. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology, 2006, 66, 1117-9. (Pubitemid 44044808)
121. Meininger V.; Drory, V.E.; Leigh, P.N.; Ludolph, A.; Robberecht, W.; Silani, V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler., 2009, 10, 378-83.
122. Gould, T.W.; Enomoto, H. Neurotrophic modulation of motor neuron development. Neuroscientist, 2009, 15, 105-16.
123. Suzuki, M.; Svendsen, C.N. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci., 2008, 31, 192-8.
124. Giehl, K.M. Trophic dependencies of rodent cortico-spinal neurons. Rev. Neurosci,, 2001, 12, 79-94. (Pubitemid 32182774)
125. Banks, G.B.; Chamberlain, J.S. Relevance of motoneuron specification and programmed cell death in embryos tp therapy of ALS. Birth Defects Res. C. Embryo Today, 2005, 75, 294-304. (Pubitemid 43244618)
126. Sendtner, M.; Schmalbruch, H.; Stockli, K.A.; Carrol, P.I.; Kreutzberg, G.W.; Thoenen, H. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature, 1992, 358, 502-4.
127. Mitsumoto, H.; Ikeda, K.; Klinkosz, B.; Cedarbaum, J.M.; Wong, V.; Lindsay, R.M. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science, 1994, 265, 1107-10. (Pubitemid 24293081)
128. Ilzecka, J. Increased serum CNTF level in patients with amyotrophic lateral sclerosis. Eur. Cytokine Netw., 2003, 14, 192-4. (Pubitemid 37249241)
129. Laaksovirta, H.; Soinila, S.; Hukkanen, V.; Roytta, M.; Soilu-Hanninen, M. Serum level of CNTF is elevated in patients with amyotrophic lateral sclerosis and correlates with site of disease onset. Eur. J. Neurol., 2008, 15, 355-9. (Pubitemid 351422390)
130. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Neurology, 1996, 46, 1244-9.
131. Miller, R.G.; Petajan, J.H.; Bryan, W.W.; Armon, C.; Barohn, R.J.; Goodpasture, J.C.; Hoagland, R.J.; Parry, G.J. et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann, Neurol., 1996, 39, 256-60. (Pubitemid 26071576)
132. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9, 669-76. (Pubitemid 36749215)
133. Lambrechts, D.; Storkebaum, E.; Carmeliet, P. VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS? Trends Mol. Med., 2004, 10, 275-82. (Pubitemid 38725895)
134. Oosthuyse, B.; Moons, L.; Storkebaum, E.; Beck, H.; Nuyens, D.; Brusselmans, K.; Van Dorpe, J.; Hellings, P. et al. Deletion of the hypoxiaresponse element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet., 2001, 28, 131-8. (Pubitemid 32538057)
135. Lambrechts, D.; Storkebaum, E.; Morimoto, M.; Del-Favero, J.; Desmet, P.; Marklund, S.L.; Wyns, S.; Thijs, V. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 2003, 383-94. (Pubitemid 36935331)
136. Sathasivam, S. VEGF and ALS. Neurosci. Res., 2008, 62, 71-8.
137. Dodge, J.C.; Treleaven, C.M.; Fidler, J.A.; Hester, M.; Haidel, A.; Handy, C.; Eagle, A.; Matthews, J.C.; Taksir, T.V.; Cheng, S.H.; Shihabuddin, L.S.; Kaspar, B.K. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther., 2010, 18, 2075-84.
138. Sakowski, S.A.; Schuyler, A.D.; Feldman, E.L. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler., 2009, 10, 62-73.
139. Kaspar, B.K.; Llado, J.; Sherkat, N.; Rothstein, J.D.; Gage, F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science, 2003, 301, 839-42. (Pubitemid 36962626)
140. Borasio, G.D.; Robberecht, W.; Leigh, P.N.; Emile, J.; Guiloff, R.J.; Jerusalem, F.; Silani, V.; Vos, P.E. et al. A placebo controlled trial of insulin-like nerve growth factor-1 in amyotrophic lateral sclerosis. Neurology, 1998, 51, 583-6. (Pubitemid 28406343)
141. Lai, E.C.; Felice, K.J.; Festoff, B.W.; Gawel, M.J.; Gelinas, D.F.; Kratz, R.; Murphy, M.F.; Natter, H.M. et al. Effect of recombinant human insulin-like growth factor-1 on progression of ALS. A placebo-controlled study. Neurology, 1997, 49, 1621-30. (Pubitemid 28015128)
142. Mitchell, J.D.; Wokke, J.H.J.; Borasio, G.D. Recombinant human insulinlike growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev, 2007, CD002064, doi: 10.1002/14651858.CD002064.pub2. (Pubitemid 351805357)
143. Sorenson, E.J.; Windbank, A.J.; Mandrekar, J.N.; Bamlet, W.R.Appel, S.H.; Armon, C.; Barkhaus, P.E.; Bosch, P. et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology, 2008, 71, 1770-5.
144. A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF study group (Phase III). Neurology, 1999, 52, 1427-33.
145. Cedarbaum, J.M.; Stambler M. Disease status and use off ventilatory support by ALS patients. DBNF study group. Amyotroph. Lateral Scler. OtherMotor Neuron Disord., 2001, 2, 19-22. (Pubitemid 32472144)
146. Kaira, S.; Genge, A.; Arnold, D.L. A prospective randomized placebocontrolled evaluation of corticoneural response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph. Lateral Scler. OtherMotor Neuron Disord., 2003, 4, 22-6. (Pubitemid 36636909)
147. Martin, L.J. Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol., 2006, 65, 1103-10. (Pubitemid 44885934)
148. Comi, G.P.; Bordoni, A.; Salani, S.; Franceschina,, L.; Sciacco, M.; Prelle, A.; Fortunato, F.; Zeviani, M. et al. Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann. Neurol., 1998, 43, 110-16. (Pubitemid 28124656)
149. Sasaki, S.; Iwata, M. Ultrastructural changes of synapses of Betz cell in patients with amyotrophic lateral sclerosis. Neurosci. Lett., 268, 1999, 29-32. (Pubitemid 29292537)
150. Menzies, F.M.; Ince, P.G.; Shaw, P.J. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem. Int., 2002, 40, 543-51. (Pubitemid 34159155)
151. Wong, P.C.; Pardo, C.A.; Borchelt, D.R.; Lee, M.K.; Copeland, N.G.; Jenkins, N.A.; Sisodia, S.S.; Cleveland, D.W.; Price, D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron, 1995, 14, 1105-16.
152. Kong, J.; Xu, Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci., 1998, 18, 3241-50. (Pubitemid 28186017)
153. Martin, L.J.; Liu, Z.; Chen, K.; Price, A.C.; Pan, Y.; Swaby, J.A.; Golden, W.C. Motor neuron degeneration in amyotrophoc lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J. Comp. Neurol., 2007, 500, 20-46. (Pubitemid 44904300)
154. Yim, M.B.; Kang, J-H.; Yim, H-S.; Kwak, H-S.; Chock, P.B.; Stadtman, E.R. A gain-of function of an amyotrophic lateral sclerosis-associated Cu, Zn-superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc. Natl. Acad. Sci. USA, 1996, 93, 5709-14. (Pubitemid 26190744)
155. Ezzi, S.A.; Urushitani, M.; Julien, J-P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem., 2007, 102, 170-8. (Pubitemid 46906269)
156. Ferri, A.; Cozzolino, M.; Crosio, C.; Nencini, M.; Casciati, A.; Gralla, E.B.; Rotilio, G.; Valentine,J.S.; Carri, M.T. Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc. Natl. Sci. USA, 2006, 103, 13860-5. (Pubitemid 44413998)
157. Goldsteins, G.; Keksa-Goldsteine, V.; Ahtiniemi, T.; Jaronen, M.; Arens, E.; Akerman, K.; Chan, R.H.; Koistinaho, J. Deleterious role of superoxide dismutase in the mitochondrial intermembrane space. J. Biol. Chem., 2008, 283, 8446-52.
158. Martin, L.J. The mitochondrial permeability transtion pore: a molecular target for amyotrophic lateral sclerosis therapy. Biochim. Biophys. Acta, 2010, 1802, 186-97.
159. Wendt, S.; Dedeoglu, A.; Speer, O.; Wallimann, T.; Beal, M.F.; Andreassen, O.A. reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Free Rad. Biol. Med., 2002, 32, 920-6. (Pubitemid 34439263)
160. Klivenyi, P.; Ferrante, R.J.; Matthews, R.T.; Bogdanov, M.B.; Klein, A.M.; Andreassen, O.A.; Mueller, G.; wermer, M.; Kaddurah-Daouk, R.; Beal, M.F. Neuroprotective effects of creatine in a transgenic animal mocel of amyotrophic lateral sclerosis. Nat. Med., 1999, 5, 347-50. (Pubitemid 29124375)
161. Snow, R.J.; Turnbull, J.; da Silva, S.; Jiang, F.; Tarnopolsky, M.A. Creatine supplementation and riluzole treatment provide similar effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience, 2003, 119, 661-7. (Pubitemid 36694794)
162. Pena-Altamira, E.; Crochemore, C.; Virgili, M.; Contestabile, A. Neurochemical correlates off differential neuroprotecdtion by long-term dietary creatine supplementation. Brain Res., 2005, 1058, 183-8. (Pubitemid 41416813)
163. Choi, J.K.; Kustermann, E.; Dedeoglu, A.; Jenkins, B.G. Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. Eur: J. Neurosci,, 2009, 30, 2143-50.
164. Pastula, D.M.; Moore, D.H.; Bedlack, R.S. Creatine for amyotrophic lateral sclerosis/motor neuron disease Cochrane Database Syst. Rev., 2010, CDCD00525.
165. Pedersen, W.A.; Mattson, M.P. No benefit of dietary restriction on disease onset or progression in amyotrophic lateral sclerosis Cu/Znsuperoxide dismutase mutant mice. Brain Res., 1999, 833, 117-20. (Pubitemid 29336153)
166. Contestabile, A. Benefits of caloric restriction on brain aging and related pathological states: understanding mechanisms to devise novel therapies. Curr. Med. Chem., 2009, 16, 350-61.
167. Dupuis, L.; Oudart, H.; René, F.; Gonzalez de Aguilar, J.L.; Loeffler, J.P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mousemodel. Proc. Natl. Acad. Sci. USA, 2004, 101, 11159-64. (Pubitemid 38989600)
168. Mather, K.; Watts, F.Z.; Carroll, M.; Whitehead, P.; Swash, M.; Cairn, N.; Burke, J. Antibody to an abnormal protein in amyotrophic lateral sclerosis identifies Lewy body-like inclusions in ALS and Lewy bodies in Parkinson's disease. Neurosci. Lett., 1993, 160, 13-16. (Pubitemid 23287590)
169. Bruijn, L.J.; Houseweart,M.K.; Kato, S.; Anderson, K.L.; Anderson, S.D.; Ohama, E.; Reaume, A.G.; Scott,R.W.; Cleveland, D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science, 1998, 281, 1851-4. (Pubitemid 28450505)
170. Pasinelli, P.; Belford, M.; Lennon, N.; Bacskai, B.; Hyman, B.; Trotti, D.; Brown, R.J. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron, 2004, 43, 19-30. (Pubitemid 38952816)
171. Watanabe, M.; Dykes-Hoberg, M.; Culotta,V.C.; Price, D.L.; Wong, P.C.; Rothstein, J.D. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol. Dis., 2001, 8, 933-41. (Pubitemid 34017087)
172. Yamanaka, K.; Cleveland, D.W. Determinants of rapid disease progression in ALS. Neurology , 2005, 65, 1859-60. (Pubitemid 43970102)
173. Sato, T.; Nakanishi, T.; Yamamoto, Y.; Andersen, P.M.; Ogawa, Y.; Fukada, K.; Zhou, Z.; Aoike, F. et al. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology, 2005, 65, 1954-7. (Pubitemid 43970117)
174. Durham, H.; Roy, J.; Doug, L.; Figlewicz, D. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol., 1997, 56, 523-30. (Pubitemid 27463093)
175. Patel, Y.J.; Payne Smith, M.D.; de Belleroche, J.; Latchman, D.S. Hsp27 and Hsp70 administered in combination have a potent protective effect against FALS-associated SOD1-mutant-induced cell death in mammalian neuronal cells. Mol. Brain Res., 2005, 134, 256-74.
176. Kieran, D.; Kalmar, B.; Dick, J.R.; Riddoch-Contreras, J.; Burnstock, G.; Greensmith, L.; Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice Nat. Med., 2004, 10, 402-5. (Pubitemid 38508519)
177. Kalmar, B.; Novoselov, S.; Gray, A.; Cheetham, M.E.; Margulis, B.; Greensmith, L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J. Neurochem., 2008, 107, 339-50.
178. Cudcowicz, M.E.; Shefner, J.M.; Simpson, E.; Grasso, D.; Yu, H.; Zhang, H.; Shui, A.; Schoenfeld, D.; Brown, R.H.; Wieland, S.; Barber, J.R.; Northeast ALS consortium. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve, 2008, 38, 837-44. (Pubitemid 351915317)
179. Phukan, J. Arimoclomol, a coinducer of heath shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs, 2010, 13, 482-96.
180. Corcoran, L.J.; Mitchison, T.J.; Liu, Q. A novel action of histone deacetylase inhibitors in a protein aggregosome disease model. Curr. Biol., 2004, 14, 488-92. (Pubitemid 38431283)
181. Monti, B.; Polazzi, E.; Contestabile, A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr. Mol. Pharmacol., 2009, 2, 95-109.
182. Sugai, F.; Yamamoto, Y.; Miyaguchi, K.; Zhou, Z.; Sumi, H.; Hamasaki, T.; Goto, M.; Sakoda, S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci., 2004, 20, 3179-83. (Pubitemid 40007312)
183. Rouaux, C.; Panteleeva, I.; René., F.; Gonzalez de Aguilar, J.L.; Dupuis, L.; Menger, Y.; Boutillier, A.L.; Loeffler, J.P. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci., 2007, 27, 5535-45. (Pubitemid 350021087)
184. Crochemore, C.; Virgili, M.; Bonamassa, B.; Canistro, D.; Pena-Altamira, E.; Paolini, M.; Contestabile, A. Long-term dietary administration of valproic acid does not affect while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis. Muscle Nerve, 2009, 39, 548-52.
185. Piepers, S.; Veldink, J.Hh.; de Jong, S.W.; van der Tweel, I.; van der Pol, W.L.; Uijtendaal, E.V.; Schelhaas, H.J.; Scheffer, H.; de Visser, M.; de Jong, J.M.; Wokke, J.H.; Groeneveld, G.J.; van den Berg, L.H. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann. Neurol., 2009, 66, 227-234.
186. Feng, H.L.; Leng, Y.; Ma, C.H.; Zhang, J.; Ren, M.; Chuang, D.M. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in amyotrophic lateral sclerosis mouse model. Neuroscience, 2008, 155, 567-72.
187. Pizzasegola, C.; Caron, I.; Baleno, C.; Ronchi, A.; Minola, C.; Carrì, M.T.; Bendotti, C. Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph. Lateral Scler., 2009, 10, 221-8.
188. Chiò, A.; Borghero, G.; Calvo, A.; Capasso, M.; Caponnetto, C., Corbo, M.; Giannini, F. Lithium carbonate in amyotrophic lateral sclerosis: lack off efficacy in a dose-finding trial. Neurology, 2010, 75, 619-25.
189. Saute, J.A.; Valler, L.; Schestatsky, P. The role of lithium in ALS remains unknown. Amyotroph. Lateral Scler., 2010, 11, 574-79.
190. Ryu, H.; Smith, K.; Camelo, S.I.; Carreras, I.; Lee, J.; Iglesias, A.H.; Dangond, F.; Cormier, K.A. et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem., 2005,93, 1087-98. (Pubitemid 40776564)
191. DelSignore, S.J.; Amante, D.J.; Kim, J.; Stack, E.C.; Goodrich, S.; Cormier, K.; Smith, K.; Cudkowicz, M.E.; Ferrante, R.J. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler., 2009, 10, 85-94.
192. Cudkowicz, M.E.; Andres, P.L.; Macdonald, S.A.; Bedlack, R.S.; Choudry, R.; Brown, R.H. Jr.; Zhang, H.; Schoenfeld, D.A. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph. Lateral Scler., 2009, 10, 99-106.
193. Welty, D.F.; Schielke, G.P.; Rothstein, J.D. Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. Ann. Pharmacother., 1995, 29, 1164-7.
194. Mazzini, L.; Mora, G.; Balzarini, C.; Brigatti, M.; Pirali, I.; Comazzi, F.; Pastore, E. The natural history and the effects off gabapentin in amyotrophic lateral sclerosis. J. Neurol. Sci., 1998, 160 Suppl. 1, S57-63. (Pubitemid 28522520)
195. Miller, R.G.; Moore, D.H. 2nd; Gelinas, D.F.; Dronsky, V.; Mendoza, M.; Barohn, R.J.; Bryan, W.; Ravits, J. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology, 2001,56, 843-8. (Pubitemid 32293584)
196. McDermott, M.P.; Rowland, L.P. ALS defeats gabapentin: reflections on another failed treatment. Neurology, 2001, 56, 826-7. (Pubitemid 32290796)
197. Federici, T.; Boulis, N.M. Gene-based treatment of motor neuron diseases. Muscle Nerve, 2006, 33, 302-23.
198. Azzouz, M. Gene therapy for ALS: progress and prospects. Biochim. Biophys. Acta, 2006, 1762, 1122-7. (Pubitemid 44750578)
199. Hester, M.E.; Foust, K.D.; Kaspar, R.W.; Kaspar, B.K. AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS. Curr. Gene Ther., 2009, 9, 428-33.
200. McCown, T. J. Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther. 2005, 5, 333-8. (Pubitemid 40895017)
201. Wong, L. F.; Goodhead, L.; Prat, C.; Mitrophanous, K. A.; Kingsman, S.M.; Mazarakis, N.D. Lentivirus-mediated gene transfer to the central nervous system: Therapeutic and research applications. Hum. Gene Ther., 2006, 17, 1-9. (Pubitemid 43102718)
202. Klein, S. M.; Behrstock, S.; McHugh, J.; Hoffmann, K.; Wallace, K.; Suzuki, M.; Aebischer, P.; Svendsen, C.N. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum. Gene Ther., 2005, 16, 509-21. (Pubitemid 40647148)
203. Azzouz, M.; Hottinger, A.; Paterna, J.C.; Zurn, A.D.; Aebischer, P.; Bueler, H. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum. Mol. Genet., 2000, 9, 803-11. (Pubitemid 30162765)
204. Yamashita, S.; Mita, S.; Kato, S.; Okado, H.; Ohama, E.; Uchino, M. Effect on motor neuron survival in mutant SOD1 (G93A) transgenic mice by Bcl-2 expression using retrograde axonal transport of adenoviral vectors. Neurosci. Lett., 2002, 328, 289-93. (Pubitemid 34876668)
205. Caplen, N.J.; Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther. 2004, 11, 1241-8. (Pubitemid 39173430)
206. Buckingham, S. D.; Esmaeili, B.; Wood, M.,; Sattelle, D. B.; RNA interference: From model organisms towards therapy for neural and neuromuscular disorders. Hum. Mol. Genet., 2004, 13, R275-R288. (Pubitemid 39359913)
207. Davis S.; Lollo, B.; Freier, S.; Esau, C.; Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res., 2006, 34, 2294-304. (Pubitemid 43985667)
208. Miller, T.M.; Kaspar, B.K.; Kops, G.J.; Yamanaka, K.; Christian, L.J.; Gage F.H.; Cleveland, D.W. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol., 2005, 57, 773-6. (Pubitemid 40628872)
209. Ralph, G.S.; Radcliffe, P.A.; Day, D.M.; Carthy, J.M.; Leroux, M.A.; Lee, D.C.; Wong, L.F.; Bilsland, L.G. et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med., 2005, 11, 429-33. (Pubitemid 40562334)
210. Raoul, C.; Abbas-Terki, T.; Bensadoun, J.C.; Guillot, S.; Haase, G.; Szulc, J.; Henderson, C.E.; Aebischer, P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med., 2005, 11, 423-8. (Pubitemid 40562333)
211. Wang, H.; Ghosh, A.; Baigude, H.; Yang, C.S.; Qiu, L.; Xia, X.; Zhou, H.; Rana, T.M.; Xu, Z. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J. Biol. Chem., 2008, 283, 15845-52.
212. Hedlund, E.; Hefferan, M.P.; Marsala, M.; Isacson, O. Cell therapy and stem cells in animal models of motor neuron disorders. Eur. J. Neurosci., 2007, 26, 1721-37. (Pubitemid 47493182)
213. Suzuki, M.; Svendsen, C.N. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci., 2008, 31, 192-8.
214. Papadeas, S.T.; Maragakis, N.J. Advances in cell research for amyotrophic lateral sclerosis. Curr. Opin. Biotechnol., 2009, 20, 545-51.
215. Dilani, V.; Calzarossa, C.; Cova, L.; Ticozzi, N. Stem cells in amyotrophic lateral sclerosis: motor neuron protection or repolacement? CNS Neurol. Disord. Drug Targets, 2010, 9, 314-24.
216. Benatar, M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis., 2007, 26, 1-13. (Pubitemid 46437445)
217. Zinman, L.; Cudkowicz, M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol., 2011, 10, 481-90.
218. Ludolph, A.C.; Bendotti, C.; Blaugrund, E.; Hengerer, B.; Loeffler, J.P.; Martin, J.; Meininger, V.; Meyer, T. et al. Guidlines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph. Lateral Scler., 2007, 8, 217-23. (Pubitemid 47190225)
219. Ludolph, A.C.; Bendotti, C.; Blaugrund, E.; Chio, A.; Greensmith, L.; Loeffler, J.P.; Mead, R.; Niessen, H.G. et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph. Lateral Scler., 2010, 11, 38-45.
220. Maruyama, H.; Morino, H.; Ito, H.; Izumi, Y.; Kato, H.; Watanabe, Y.; Kinoshita, Y.; Kamada, M. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature, 2010, 465, 223-6.
221. Deng, H.X.; Bigio, E.H.; Zhai, H.; Fecto, F.; Ajroud, K.; Shi, Y.; Yan, J.; Mishra, M. et al. Differential involvement of optineurin in amyotrophic lateral sclerosis with or without SOD1 mutations. Arch. Neurol., 2011, 68, 1057-61.
222. Hortobagyi, T.; Troakes, C.; Nishimura, A.L.; Vance, C.; van Swieten, J.C.; Seelaar, H.; Al-Sarrai, S. et al Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. Acta Neuropathol., 2011, 121, 519-27.S
223. Kwiatkowski T.J. Jr.; Bosco, D.A.; Leclerc, A.L.; Tamrazian, E.; Vanderburg, C.R.; Russ, C.; Davis, A.; Gilchrist, J. et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 2009, 323, 1205-8.
224. Kabashi, E.; Bercier, V.; Lissouba, A.; Liao, M.; Brustein, E.; Rouleau, GA.; Drapeau, P. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet., 2011, 7: e1002214.
225. Huang, C.; Zhou, H.; Tong, J.; Chen, H.; Liu, Y.J.; Wang, D.; Wei, X.; Xia, X.G. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet., 2011, 7: e1002011.
226. Lanson, N.A. Jr.; Maltare, A.; King, H.; Smith, R.; Kim, J.H.; Taylor, J.P.; Lloyd, T.E.; Pandey, U.B. A drosophila model of FUS-related neurodegeneration reveals genetic interactions between FUS and TDP-43. Hum. Mol. Genet., 2011, 20, 2510-23.
227. King, A.; Maekawa, S.; Bodi, I.; Troakes, C.; Al-Sarrai, S. Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP-43 proteinopathies but are only rarely additionally immunopositivefor phosphorylation-dependent TDP-43. Neuropathology, 2011, 31, 239-49.